Topoisomerase IIα expression rather than gene amplification predicts responsiveness of adjuvant anthracycline-based chemotherapy in women with primary breast cancer

Journal of Cancer Research and Clinical Oncology

Volumn 136, Issue 7, 2010, Pages 1029-1037

  Schindlbeck, Christian ^a   Mayr, D ^a   Olivier, C ^a   Rack, B ^a   Engelstaedter, V ^a   Jueckstock, J ^a   Jenderek, C ^a   Andergassen, U ^a   Jeschke, U ^a   Friese, K ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Anthracyclines; Breast cancer; Chemotherapy; HER2; Topoisomerase

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE; DNA TOPOISOMERASE IIALPHA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE II ALPHA; HER2 PROTEIN, HUMAN; TUMOR ANTIGEN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DELETION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; BIOSYNTHESIS; BREAST TUMOR; CANCER STAGING; COHORT ANALYSIS; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; PREDICTION AND FORECASTING; RETROSPECTIVE STUDY;

ADULT; AGED; ANTHRACYCLINES; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 77953231299     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-009-0748-4     Document Type: Article

References (31)

1. E Arriola SM Rodriguez-Pinilla MB Lambros RL Jones M James K Savage, et al. 2007 Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer Breast Cancer Res Treat 106 2 181 189 10.1007/s10549-006-9492-5 1:CAS:528:DC%2BD2sXht1CgtL7M 17260090 (Pubitemid 350045015)
2. DA Berry KA Cronin SK Plevritis DG Fryback L Clarke M Zelen, et al. 2005 Effect of screening and adjuvant therapy on mortality from breast cancer N Engl J Med 353 17 1784 1792 10.1056/NEJMoa050518 1:CAS:528:DC%2BD2MXhtFKrtLbN 16251534 (Pubitemid 41549890)
3. RC Coombes JM Bliss J Wils F Morvan M Espie D Amadori, et al. 1996 Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group J Clin Oncol 14 1 35 45 1:CAS:528:DyaK28XhtVOjtrY%3D 8558217
4. F Cortes N Pastor S Mateos I Dominguez 2003 Roles of DNA topoisomerases in chromosome segregation and mitosis Mutat Res 543 1 59 66 10.1016/S1383- 5742(02)00070-4 1:CAS:528:DC%2BD38XpvVahsLs%3D 12510017 (Pubitemid 36050912)
5. M Cuadros R Villegas 2009 Systematic review of HER2 breast cancer testing Appl Immunohistochem Mol Morphol 17 1 1 7 10.1097/PAI.0b013e318169fc1c 1:CAS:528:DC%2BD1cXhsFajtL7P 18685491
6. M De Laurentiis G Cancello D D'Agostino M Giuliano A Giordano E Montagna, et al. 2008 Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials J Clin Oncol 26 1 44 53 10.1200/JCO.2007.11.3787 18165639
7. A Di Leo D Gancberg D Larsimont M Tanner T Jarvinen G Rouas, et al. 2002 HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil Clin Cancer Res 8 5 1107 1116 1:CAS:528:DC%2BD38XksVSqu7s%3D 12006526
8. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687-1717
9. A Gennari MP Sormani P Pronzato M Puntoni M Colozza U Pfeffer, et al. 2008 HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials J Natl Cancer Inst 100 1 14 20 1:CAS:528:DC%2BD1cXit1Cku7o%3D 18159072
10. LN Harris G Broadwater M Abu-Khalaf D Cowan AD Thor D Budman, et al. 2009 Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013 J Clin Oncol 27 21 3430 3436 10.1200/JCO.2008.18.4085 1:CAS:528:DC%2BD1MXhtVSqtLvL 19470942
11. DG Hicks BJ Yoder J Pettay E Swain S Tarr M Hartke, et al. 2005 The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization study Hum Pathol 36 4 348 356 10.1016/j.humpath.2005.01.016 1:CAS:528:DC%2BD2MXjsFGqs7Y%3D 15891995 (Pubitemid 40591804)
12. TA Jarvinen ET Liu 2003 HER-2/neu and topoisomerase IIalpha in breast cancer Breast Cancer Res Treat 78 3 299 311 10.1023/A:1023077507295 12755489 (Pubitemid 36543210)
13. RL Jones C Swanton MS Ewer 2006 Anthracycline cardiotoxicity Expert Opin Drug Saf 5 6 791 809 10.1517/14740338.5.6.791 1:CAS:528:DC%2BD28XhtVyqsbfE 17044806 (Pubitemid 44669494)
14. S Jones FA Holmes J O'Shaughnessy JL Blum SJ Vukelja KJ McIntyre, et al. 2009 Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin, cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735 J Clin Oncol 27 8 1177 1183 10.1200/JCO.2008.18. 4028 1:CAS:528:DC%2BD1MXktFKhs7c%3D 19204201
15. MN Levine KI Pritchard VH Bramwell LE Shepherd D Tu N Paul 2005 Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5 J Clin Oncol 23 22 5166 5170 10.1200/JCO.2005.09.423 1:CAS:528:DC%2BD2MXpsFWmtb8%3D 16051958 (Pubitemid 46224025)
16. M Martin A Villar A Sole-Calvo R Gonzalez B Massuti J Lizon, et al. 2003 Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group Ann Oncol 14 6 833 842 10.1093/annonc/mdg260 1:STN:280:DC%2BD3s3mvFGnsw%3D%3D 12796019 (Pubitemid 36827198)
17. M Martin-Richard M Munoz J Albanell L Colomo M Bellet MJ Rey, et al. 2004 Serial topoisomerase II expression in primary breast cancer and response to neoadjuvant anthracycline-based chemotherapy Oncology 66 5 388 394 10.1159/000079487 1:CAS:528:DC%2BD2cXntFSgt74%3D 15331926 (Pubitemid 39194361)
18. KV Nielsen B Ejlertsen S Moller JT Jorgensen A Knoop H Knudsen, et al. 2008 The value of TOP2A gene copy number variation as a biomarker in breast cancer: update of DBCG trial 89D Acta Oncol 47 4 725 734 10.1080/ 02841860801995396 1:CAS:528:DC%2BD1cXnsFeiur8%3D 18465341 (Pubitemid 351878451)
19. FP O'Malley S Chia D Tu LE Shepherd MN Levine VH Bramwell, et al. 2009 Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy J Natl Cancer Inst 101 9 644 650 10.1093/jnci/djp067 19401546
20. L Orlando B Del Curto S Gandini R Ghisini E Pietri R Torrisi, et al. 2008 Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer Breast 17 5 506 511 10.1016/j.breast.2008.03.007 18456496
21. KI Pritchard LE Shepherd FP O'Malley IL Andrulis D Tu VH Bramwell, et al. 2006 HER2 and responsiveness of breast cancer to adjuvant chemotherapy N Engl J Med 354 20 2103 2111 10.1056/NEJMoa054504 1:CAS:528:DC%2BD28XkslCku7s%3D 16707747 (Pubitemid 43736610)
22. W Remmele HE Stegner 1987 Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue Pathologe 8 3 138 140 1:STN:280: DyaL2s3ovFGhsQ%3D%3D 3303008
23. JS Ross JA Fletcher 1998 The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy Stem Cells 16 6 413 428 10.1002/stem.160413 1:STN:280:DyaK1M%2FkvVOjtQ%3D%3D 9831867
24. M Ryberg D Nielsen G Cortese G Nielsen T Skovsgaard PK Andersen 2008 New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients J Natl Cancer Inst 100 15 1058 1067 10.1093/jnci/djn206 1:CAS:528:DC%2BD1cXpslWktrg%3D 18664656
25. C Schindlbeck T Kampik W Janni B Rack U Jeschke S Krajewski, et al. 2005 Prognostic relevance of disseminated tumor cells in the bone marrow and biological factors of 265 primary breast carcinomas Breast Cancer Res 7 6 R1174 R1185 10.1186/bcr1360 16457698
26. DJ Slamon MF Press 2009 Alterations in the TOP2A and HER2 genes: association with adjuvant anthracycline sensitivity in human breast cancers J Natl Cancer Inst 101 9 615 618 10.1093/jnci/djp092 1:CAS:528: DC%2BD1MXlvVWlurY%3D 19401550
27. M Tanner J Isola T Wiklund B Erikstein P Kellokumpu-Lehtinen P Malmstrom, et al. 2006 Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored, dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401 J Clin Oncol 24 16 2428 2436 10.1200/JCO.2005.02.9264 1:CAS:528:DC%2BD28XmtVOmsLc%3D 16682728 (Pubitemid 46630618)
28. N Tinari R Lattanzio C Natoli E Cianchetti D Angelucci E Ricevuto, et al. 2006 Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival Clin Cancer Res 12 5 1501 1506 10.1158/1078-0432.CCR-05-0978 1:CAS:528:DC%2BD28XitVGms7w%3D 16533774
29. R Tubbs WE Barlow GT Budd E Swain P Porter A Gown, et al. 2009 Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status J Clin Oncol 27 24 3881 3886 10.1200/JCO.2008.20.1566 1:CAS:528:DC%2BD1MXhtFCgsb3P 19620488
30. P Vici G Viola C Botti S Rossi C Vitucci S Corsetti, et al. 2008 Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients Clin Ter 159 6 449 452 1:STN:280:DC%2BD1M%2Fps1Smsw%3D%3D 19169607
31. JC Wang 2002 Cellular roles of DNA topoisomerases: a molecular perspective Natl Rev Mol Cell Biol 3 6 430 440 10.1038/nrm831 1:CAS:528:DC%2BD38XltlartLw%3D (Pubitemid 34685700)